AngioSoma Inc
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, engages in the provision of patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases in the United States. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is base… Read more
Market Cap & Net Worth: AngioSoma Inc (GSTC)
AngioSoma Inc (PINK:GSTC) has a market capitalization of $248.22K ($248.22K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #40522 globally and #13137 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AngioSoma Inc's stock price $0.00 by its total outstanding shares 1241105695 (1.24 Billion).
AngioSoma Inc Market Cap History: 2015 to 2025
AngioSoma Inc's market capitalization history from 2015 to 2025. Data shows change from $1.63 Billion to $248.22K (-61.33% CAGR).
AngioSoma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AngioSoma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
122498.74x
AngioSoma Inc's market cap is 122498.74 times its annual revenue
1728.56x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $39.72 Million | $890.00 | -$817.00K | 44624.02x | N/A |
| 2019 | $3.85 Million | $425.00 | -$675.00K | 9052.77x | N/A |
| 2020 | $9.43 Million | $77.00 | -$779.79K | 122498.74x | N/A |
| 2020 | $9.43 Million | $77.00 | -$542.00K | 122498.74x | N/A |
Competitor Companies of GSTC by Market Capitalization
Companies near AngioSoma Inc in the global market cap rankings as of March 18, 2026.
Key companies related to AngioSoma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
AngioSoma Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, AngioSoma Inc's market cap moved from $1.63 Billion to $ 248.22K, with a yearly change of -61.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $248.22K | -50.00% |
| 2024 | $496.44K | -55.56% |
| 2023 | $1.12 Million | -93.23% |
| 2022 | $16.51 Million | +14.66% |
| 2021 | $14.40 Million | +52.63% |
| 2020 | $9.43 Million | +145.16% |
| 2019 | $3.85 Million | -90.31% |
| 2018 | $39.72 Million | -96.79% |
| 2017 | $1.24 Billion | -35.74% |
| 2016 | $1.92 Billion | +18.32% |
| 2015 | $1.63 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of AngioSoma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $248.22K USD |
| MoneyControl | $248.22K USD |
| MarketWatch | $248.22K USD |
| marketcap.company | $248.22K USD |
| Reuters | $248.22K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.